Two of the three biggest western vaccine makers tried to calm fears over a new coronavirus strain, with the University of Oxford and BioNTech predicting existing jabs would continue to prevent severe disease.
Markets had fallen earlier on Tuesday after the chief executive of Moderna, the third big vaccine maker, told the Financial Times that existing vaccines were likely to be much less effective against the Omicron variant and it would take months to manufacture replacement jabs at scale.
“There is no world, I think, where [the effectiveness] is the same level . . . we had with [the] Delta [variant],” Stéphane Bancel said in an interview at Moderna’s headquarters in Massachusetts.
您已阅读15%（689字），剩余85%（3806字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。